What Autoimmune Diseases Are Linked to MTHFR?

MTHFR gene variants have been statistically linked to several autoimmune diseases, most consistently rheumatoid arthritis and systemic lupus erythematosus, with more mixed evidence for inflammatory bowel disease, multiple sclerosis, and autoimmune thyroid conditions. The connection runs through a metabolic pathway that affects both inflammation and how your genes get switched on and off. But the size of the added risk varies widely depending on the disease, the specific variant involved, and your ethnic background, and major medical societies still advise against routine MTHFR testing because the results rarely change what your doctor would actually do.

How MTHFR Variants Affect the Immune System

The MTHFR gene provides instructions for an enzyme that converts one form of folate into its active form, 5-methyltetrahydrofolate, which the body then uses to recycle homocysteine back into methionine.¹ The two most studied variants are C677T and A1298C. People with two copies of the C677T variant have a version of the enzyme that works at roughly 30% of normal capacity, while those with two copies of A1298C retain about 60% activity.² When this enzyme underperforms, two things happen that matter for autoimmunity.

First, homocysteine builds up. Elevated homocysteine drives oxidative stress in blood vessels and triggers pro-inflammatory signaling: immune cells get recruited to vessel walls, adhesion molecules ramp up on the cells lining blood vessels, and inflammatory chemicals attract more immune cells into tissues where they can cause damage.³ This creates a low-grade inflammatory environment that can feed into autoimmune flares.

Second, reduced MTHFR activity limits the supply of S-adenosylmethionine (SAM), the molecule your cells use to add chemical tags to DNA. These tags, called methyl groups, help control which genes are active and which stay silent. In autoimmune conditions like rheumatoid arthritis, T cells and joint tissue show less methylation than normal, and this is worsened when folate availability drops due to MTHFR variants. In lupus, a similar pattern appears in CD4+ T cells, where under-methylation is tied to an overactive interferon response.⁴ So MTHFR variants do not directly cause autoimmune disease. They constrain a metabolic pathway that, when impaired, can tip the immune system toward the kind of dysregulation seen in multiple autoimmune conditions.

Rheumatoid Arthritis

Rheumatoid arthritis (RA) has the strongest and most consistent evidence linking it to MTHFR variants. A systematic review and meta-analysis pooling data from multiple studies found that both the C677T and A1298C variants were associated with increased RA susceptibility. People carrying the C677T T allele had roughly 30% higher odds of developing RA, while those homozygous for the A1298C variant had about 58% higher odds compared to people without the variant.⁵ A separate meta-analysis based on 16 studies confirmed the positive association for C677T across dominant, recessive, and allelic models, with the strongest signals in African populations and, for certain genetic models, in Asian populations.⁶

To be clear, a 30-60% increase in odds is a modest effect. It does not mean carrying the variant will give you RA. Many people with these variants never develop the disease, and many RA patients carry the normal version of the gene. But the consistency of the signal across different populations and study designs suggests the link is real, not a statistical artifact. The epigenetic mechanism described above, where MTHFR variants contribute to hypomethylation in immune cells, fits well with what is known about RA biology at the molecular level.⁴

Systemic Lupus Erythematosus

Lupus shows a connection to MTHFR variants as well, though the picture is more complicated. A meta-analysis looking at the C677T variant (rs1801133) across multiple populations found that carrying the T allele was associated with a higher risk of developing lupus overall. The signal was especially strong in Asian populations, where the risk increase was several-fold.⁷ Interestingly, a separate study in an Egyptian cohort did not find a significant link between C677T and lupus susceptibility but did find that the A1298C variant mattered: people carrying the AC or CC genotypes at that position had about 70% higher odds of developing lupus, and the CT haplotype combining both variants roughly doubled the risk.⁸

Beyond susceptibility, MTHFR variants appear to worsen cardiovascular complications in lupus patients, which is relevant because heart and blood vessel disease is a leading cause of death in people with lupus. In one study, lupus patients with the 677TT genotype had about five times the odds of developing arterial plaque, even after accounting for traditional risk factors like cholesterol, blood pressure, and smoking. High homocysteine levels showed a similarly elevated risk.⁹ For lupus patients who already face an elevated cardiovascular burden from their disease, carrying an MTHFR variant that further raises homocysteine and promotes vascular inflammation is a meaningful additional concern.

Inflammatory Bowel Disease

The relationship between MTHFR and inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is less tidy. An early British study found that homozygosity for the C677T variant was roughly twice as common in both ulcerative colitis and Crohn’s disease patients compared to healthy controls.¹⁰ However, a later study in a Moroccan population found no statistically significant association between C677T and either form of IBD.¹¹

The A1298C variant may be the more relevant player for IBD. A meta-analysis that combined data from multiple studies found that carrying the AC or CC genotype at position 1298 was associated with about a 26% increase in overall IBD risk, with a somewhat stronger signal for ulcerative colitis specifically.¹² The inconsistency across populations is a recurring theme in MTHFR research. The frequency of these variants differs dramatically by ethnicity, and so do dietary folate levels, which can offset some of the metabolic consequences of carrying the variant. A population eating folate-rich diets may not see the same disease associations as one with lower folate intake.

Multiple Sclerosis and a Surprising Reversal

Multiple sclerosis (MS) presents the most interesting wrinkle in the MTHFR-autoimmunity story, because the evidence points in opposite directions depending on the type of study. A case-control study in a Southern Iranian population found a strong positive association between MTHFR variants and MS risk, with people homozygous for 677T having over six times the odds of developing MS compared to those with the normal genotype. Combining both variants produced even higher risk estimates.¹³

But a large-scale genetic analysis using Mendelian randomization, which is generally considered a more reliable method for establishing causal direction, reached the opposite conclusion. That study found that the homocysteine-raising T allele at C677T was actually associated with a reduced risk of MS, with about a 9% lower odds of MS per copy of the allele. When scaled to the full effect of genetically elevated homocysteine from MTHFR, the estimated protective effect was about 27%.¹⁴ The researchers proposed that the protective effect might be mediated through one-carbon metabolism’s influence on immune cell function, rather than through homocysteine itself.

This disagreement has not been fully resolved. One explanation is that the Iranian case-control study, like all observational studies, is vulnerable to confounding factors that Mendelian randomization can partially avoid. Another is that regional dietary and environmental factors might modify the relationship. For now, the evidence does not clearly support MTHFR variants as a risk factor for MS, and the Mendelian randomization data suggests the relationship might even run in a counterintuitive direction.

Autoimmune Thyroid Disease

The evidence for autoimmune thyroid disease, which includes both Hashimoto’s thyroiditis and Graves’ disease, is split. A study looking at adults with autoimmune thyroid disease found no correlation between MTHFR variants (at either position 677 or 1298) and the development or prognosis of the condition.¹⁵ However, a more recent case-control study focused specifically on children and adolescents with Hashimoto’s thyroiditis found that young patients with the condition were about 2.5 times more likely to carry the 677T allele compared to healthy peers. Those who did carry it also had about twice the frequency of abnormal thyroglobulin antibodies.¹⁶

Whether the age of the population studied explains the discrepancy is unclear. Pediatric Hashimoto’s may involve somewhat different genetic contributors than the adult form, or the adult study may have had a population where folate status was adequate enough to mask the effect of the variant. This is an area where the research is genuinely thin and it would be premature to draw strong conclusions.

Psoriasis and Celiac Disease

A few other autoimmune conditions show up in the MTHFR literature, though with less depth. Psoriasis, an inflammatory skin condition driven by immune overactivity, has been studied in connection with MTHFR variants with a surprising twist. One study found that patients who carried the C677T variant actually had less severe disease, not more. Among patients with the normal (CC) genotype, about 38% had severe psoriasis, compared to roughly 8-13% of those with one or two copies of the T allele.¹⁷ The variant may not increase your risk of getting psoriasis, but if you do have it, the associated metabolic changes might paradoxically dampen its severity. This is a single study and far from settled science, but it illustrates that MTHFR’s influence on autoimmunity is not always in the direction you would expect.

Celiac disease is also part of this conversation. The hallmark of celiac disease is intestinal damage triggered by gluten, and this damage impairs folate absorption, creating a metabolic double hit in people who already have reduced MTHFR function. Research has documented that celiac patients can carry MTHFR variants alongside elevated homocysteine,¹⁸ and a review of the epigenetic landscape in celiac disease has noted that intestinal cells show reduced methylation of repetitive DNA elements, driven by both gluten-induced tissue damage and folate malabsorption.⁴ Whether MTHFR variants increase the risk of developing celiac disease in the first place, or simply worsen its metabolic consequences, has not been clearly established.

When MTHFR and Autoimmune Disease Overlap With Blood Clot Risk

Autoimmune diseases can carry their own thrombotic risks, and MTHFR variants may compound them. Antiphospholipid syndrome (APS), an autoimmune condition defined by antibodies that promote abnormal clotting, is a good example. A case report documented a young man who developed unprovoked blood clots and was found to have both APS and compound heterozygous MTHFR mutations (carrying one copy of each variant) alongside elevated homocysteine.¹⁹ While case reports cannot establish how common this overlap is, they highlight that for people with autoimmune conditions that already predispose to clotting, the added pro-inflammatory and vascular effects of high homocysteine from MTHFR variants could meaningfully increase that risk.

Why MTHFR Status Matters for Methotrexate

Even if MTHFR testing is not widely recommended for predicting autoimmune disease risk, it has a more practical relevance in the treatment of those diseases. Methotrexate is one of the most commonly prescribed drugs for rheumatoid arthritis and is also used in lupus and psoriasis. It works in part by interfering with folate metabolism, the same pathway MTHFR operates in, which means your MTHFR status can influence how well you tolerate the drug.

A systematic review and meta-analysis found that the C677T variant was associated with increased methotrexate toxicity, including side effects like liver enzyme elevation, mouth sores, and low blood counts, in both East Asian and Caucasian patients. Interestingly, even patients who were taking folic acid supplements alongside methotrexate still showed elevated toxicity risk if they carried the variant.²⁰ An Algerian study echoed this, finding that the 677T allele tripled the odds of methotrexate side effects. That same study found the A1298C variant played a role in treatment effectiveness: patients with the A allele at that position were about three times more likely to have a good or moderate response to the drug.²¹

The relationship between A1298C and methotrexate is not entirely straightforward. A separate study of rheumatoid arthritis patients found that the 1298CC genotype was actually associated with fewer methotrexate side effects, with patients carrying the normal AA genotype having roughly five times the odds of adverse effects compared to those with CC.²² This seems counterintuitive, given that the variant reduces enzyme activity, but it may reflect complex interactions between reduced enzyme function, folate trapping, and the specific way methotrexate acts on the pathway. The clinical takeaway: if you are on methotrexate and experiencing persistent side effects despite folic acid supplementation, MTHFR status is one factor that could help explain it.

What Medical Guidelines Say About MTHFR Testing

Despite all these associations, the official position of major medical societies is that routine MTHFR testing is not recommended. A review of the evidence and guidelines noted that MTHFR testing is frequently ordered for conditions ranging from blood clotting disorders to recurrent miscarriage to cardiovascular disease, but the results do not change how patients are managed or treated.²³ The reasoning is straightforward: even if you test positive for a variant, the standard medical advice — eat a diet adequate in folate, take supplemental folic acid or methylfolate if indicated, monitor and manage homocysteine if elevated — does not require knowing your MTHFR genotype. Your doctor would give you the same guidance regardless.

This does not mean the research is useless. The associations with RA and lupus are strong enough to have potential value in understanding why some populations have higher disease burdens, or why some patients respond poorly to methotrexate. And the epigenetic research connecting MTHFR to immune cell methylation patterns may eventually inform more targeted therapies. But for the individual patient sitting in a doctor’s office, a positive MTHFR test is unlikely to change the plan. The gap between “statistically associated in population studies” and “clinically actionable for you personally” remains wide.

Methylfolate Versus Folic Acid

One question that comes up constantly in online MTHFR discussions is whether people with variants should take methylfolate (the active form, also called L-methylfolate or 5-MTHF) instead of regular folic acid. The logic makes intuitive sense: if your enzyme is sluggish at converting folate to its active form, skip the conversion step entirely by taking the pre-activated version. A small comparative study in women with MTHFR variants and recurrent pregnancy loss found that those taking methylfolate had substantially better outcomes than those taking regular folic acid, including higher rates of reaching full-term pregnancy and fewer pregnancy complications.²⁴

That said, this was a single small study in a specific clinical context, not a broad endorsement of methylfolate for all MTHFR carriers. The body can still use folic acid even with reduced MTHFR activity; the enzyme is sluggish, not absent. Most guidelines for conditions like neural tube defect prevention still recommend standard folic acid, partly because it has decades of safety data and the methylfolate research base is comparatively thin. If you carry an MTHFR variant and are interested in switching, it is a conversation worth having with a doctor who understands your full clinical picture, but the evidence has not reached the point where methylfolate is the default recommendation over folic acid for most situations.